Sertraline improves executive function in patients with vascular cognitive impairment

Donald R. Royall, Jeffrey A. Cordes, Gustavo Román, Angela Velez, Aaron Edwards, Jason S. Schillerstrom, Marsha J. Polk

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


The authors reviewed 35 open-label sertraline trials for executive impairment in ischemic cerebrovascular disease. Outcomes included clockdrawing, the Executive Interview (EXIT25), the Geriatric Depression Scale, and the Mini-Mental State Examination. Clinically "meaningful" improvement was defined as a >3.0 EXIT25 point decline from baseline. "Remission" was defined as the achievement of an EXIT25 score <15/50. Only EXIT25 scores improved significantly. Twenty patients (57.1%) experienced a clinically meaningful improvement in executive control function. Twelve (34.3%) achieved remission. Our findings suggest that sertraline may have both statistical and clinically meaningful effects on executive control function in ischemic cerebrovascular disease. The authors discuss the implications for future clinical trials.

Original languageEnglish (US)
Pages (from-to)445-454
Number of pages10
JournalJournal of Neuropsychiatry and Clinical Neurosciences
Issue number4
StatePublished - 2009

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Sertraline improves executive function in patients with vascular cognitive impairment'. Together they form a unique fingerprint.

Cite this